

Special Issue

New Perspectives on Neuronal Cytoskeletal Dysregulation in Health and Disease

Message from the Guest Editors

Neurons have distinct and specialized morphological characteristics that allow them to receive, process, and transmit information. Because axons in humans can extend up to one meter in length, the presence of both the neuronal cytoskeleton and mitochondria is required to establish and maintain the polarity and physiological properties of these enormous structures. The neuronal cytoskeleton is made up of actin filaments, intermediate filaments, and microtubules, which help to transmit electrical and chemical signals between neurons and regulate the balance between motility and stability in neuronal structures. Articles focused on understanding the pathophysiology of the neuronal cytoskeleton and Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and many other neurodegenerative diseases and/or their synergistic effects during CNS disorders are welcome in this Special Issue.

Guest Editors

Dr. Arjun Singh

Molecular Pharmacology Program, Laboratory of Signal Transduction, Mortimer B. Zuckerman Research Center, 417 East 68th Street, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

Dr. Rajvir Singh

Molecular Pharmacology Program, Laboratory of Signal Transduction, Mortimer B. Zuckerman Research Center, 417 East 68th Street, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

Deadline for manuscript submissions

closed (20 December 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/140243

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).